Discovery of Pyrrolopyridine−Pyridone Based Inhibitors of Met Kinase: Synthesis, X-ray Crystallographic Analysis, and Biological Activities | Journal of Medicinal Chemistry
Metabolomics reveals tepotinib‐related mitochondrial dysfunction in MET‐activating mutations‐driven models - Poliaková - 2019 - The FEBS Journal - Wiley Online Library
RCSB PDB Group Summary: 910_30
MicroRNA-206 suppresses mesothelioma progression via the Ras signaling axis: Molecular Therapy - Nucleic Acids
ANALYTICAL REPORT1
Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1α levels under hypoxia | Oncogene
Cancers | Free Full-Text | Shifting the Gears of Metabolic Plasticity to Drive Cell State Transitions in Cancer
CP.PHAR.249 Dimethyl Fumarate (Tecfidera), Diroximel Fumarate (Vumerity)
CRITERIA FOR DRUG COVERAGE Tenofovir alafenamide (Vemlidy)
Qmx Laboratories - 4-AcO-METFumarate
Renal-Cell Carcinoma | NEJM
Metabolic rewiring in the promotion of cancer metastasis: mechanisms and therapeutic implications | Oncogene
Antioxidants | Free Full-Text | Selenomethionine (Se-Met) Induces the Cystine/Glutamate Exchanger SLC7A11 in Cultured Human Retinal Pigment Epithelial (RPE) Cells: Implications for Antioxidant Therapy in Aging Retina
Prior Authorization - Multiple Sclerosis – Vumerity® (diroximel fumarate delayed-release capsules)
4-hydroxy MET (4-HO MET, Metocin, CAS Number: 77872-41-4) | Cayman Chemical
Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis
PHARMACY POLICY STATEMENT
Psilacetin derivatives: fumarate salts of the methyl–ethyl, methyl–allyl and diallyl variants of the psilocin prodrug - ScienceDirect
Frontiers | Physiological Perspectives on the Use of Triheptanoin as Anaplerotic Therapy for Long Chain Fatty Acid Oxidation Disorders
Tyr-Gly-Gly-Phe-Met-OH (Met-Enkephalin) | Opioid Receptor Activator | MedChemExpress
Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials - The Lancet
![1445751-40-5 | 4-Acetoxy-N-ethyl-N-methyltryptamine | 3-[2-(Ethylmethylamino)ethyl]-1H-Indol-4-ol 4-Acetate; 4-AcO-MET ; | C15H20N2O2 | TRC](https://www.trc-canada.com/prod-img/A190280.png "1445751-40-5 | 4-Acetoxy-N-ethyl-N-methyltryptamine | 3-[2-(Ethylmethylamino)ethyl]-1H-Indol-4-ol 4-Acetate; 4-AcO-MET ; | C15H20N2O2 | TRC")
1445751-40-5 | 4-Acetoxy-N-ethyl-N-methyltryptamine | 3-[2-(Ethylmethylamino)ethyl]-1H-Indol-4-ol 4-Acetate; 4-AcO-MET ; | C15H20N2O2 | TRC
Breztri Aerosphere Phase III trial meets primary endpoints
4-Acetoxy-N-methyl-N-ethyltryptamine Fumarate (4-AcO-MET Fumarate; 4-Acetoxy-MET Fumarate), 10 mg
